EGFR and non-small cell lung carcinoma: Mefatinib at either dose of 60 or 80 mg once daily achieved an ORR of 84.9%, DCR of 97.2%, median PFS of 15.4 months, and median OS of 31.6 months in the first-line treatment of patients with EGFR-mutant stage IIIB-IV NSCLC.